Pharma style companies that are at the absolute mercy of regulatory agencies and would see detrimental price collapses if trials and reviews don't go their way are just something I'd never be comfortable holding in my portfolio.
A lot of forward revenue is priced in. I mean, the company made $300,000 last year and is valued at $2.2 billion. You can probably see the anticipation that is priced in.